Speed in drug discovery is rare. Doing it without cutting quality is even rarer.
Evotec SE and Almirall have announced the nomination of a preclinical development candidate (PDC) from their dermatology alliance—marking a key step toward clinical development.
The standout detail: they got there in just two years.
Moving from early discovery to a preclinical candidate typically takes longer. This program compressed that timeline significantly—while still delivering a high-quality small molecule candidate.
The focus:
These include chronic, complex conditions where current therapies often fall short.
This wasn’t luck. It was infrastructure. Evotec deployed its integrated, AI/ML-enabled discovery platform, combining:
All connected through a data-driven workflow. The key advantage: rapid iteration.
That’s how timelines shrink without compromising candidate quality.
This is a classic capability pairing:
Almirall’s focus:
The collaboration combines technical execution with therapeutic specialization.
The program now moves toward clinical readiness. Evotec will lead this phase using its INDiGO platform—an integrated system designed to:
If successful, this sets up the candidate for first-in-human trials.
The deal structure reflects typical biotech-pharma partnerships:
Translation: high risk, high reward—tied to execution.
Immune-mediated skin diseases are gaining attention for a reason:
Small molecules—if effective—offer advantages:
That’s the opportunity this program is chasing.
This is a promising milestone—but still early. Key questions going forward:
One thing is clear: Evotec is making a strong case that AI-driven, integrated discovery isn’t just hype—it can materially compress timelines when executed well.